Company Information

  

Address: 5 WEST FORSYTH STREET
SUITE 200 
City: JACKSONVILLE 
State: FL 
Zip Code: 32202 
Telephone: (904) 516-5436 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease. We are also developing a proprietary technology to improve the ability of the cellular immune system to recognize and destroy diseased cells. This DNA expression technology named Polystart is in preclinical development. Our Cancer Vaccines In contrast to standard therapies for cancer treatment including surgery, radiation therapy and chemotherapy that imprecisely target cancer cells and normal cells, we are developing vaccines that precisely target candidate breast cancer(s), colorectal cancer(s), ovarian cancer(s) and non-small cell lung cancer(s).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.04NAN/E
03/20170.16NA28.06
12/2016-0.72NAN/E
09/20161.11NA6.03
06/2016171.37NA0.04

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.02Total Liab/Total Assets0.22
Net Inc/Total Assets-0.31Total Liab/Inv Cap0.28
Net Inc/Inv Cap-0.40Total Liab/Comm Equity0.01
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.00
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio4.56
Inventory TurnoverNACurrent Ratio4.56
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.19 1.43 1.13 1.61
Operating Income -2.39 -2.42 -1.59 -2.72
Interest Exp NA NA 0.00 NA
Pretax Income -1.89 -2.42 -1.58 -2.10
Other Income 0.50 -0.00 0.01 0.62
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.89 -2.42 -1.58 -2.10

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 9.96 5.93 7.85 9.59
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 10.14 6.11 7.92 9.70
Net Property, Plant & Equipment NA NA NA NA
Total Assets 10.14 6.11 7.92 9.70
Liabilities        
Accounts Payable 1.56 1.45 1.22 1.68
Debt in Current Liabilities 0.02 0.02 0.02 0.03
Total Current Liabilities 1.58 1.96 1.74 2.20
Long-Term Debt NA NA NA NA
Total Liabilities 1.58 1.96 1.74 2.20
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -150.75 -148.24 -145.82 -144.24
Treasury Stock NA NA NA NA
Total Stockholders' Equity 8.57 4.14 6.18 7.49
Total Liabilities and Stockholders' Equity 10.14 6.11 7.92 9.70

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -2.01 -1.92 -1.75 -1.97
Net Cash Provided by Investing Activities NA NA NA NA
Net Cash Provided by Financing Activities 6.05 0.00 0.02 7.79

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-6.17--
12/20130.00-5.53--
12/20140.00-30.88--
12/20150.00-34.07--
12/20160.00-2.46-0.72
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/179190.19




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.